Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies Prices Public Offering of Stock

NEW YORK – Immune cell sequencing firm Adaptive Biotechnologies said after the close of the market on Thursday that it is selling 8 million shares of common stock at $26.50 per share.

The firm is selling the shares on behalf of certain investors and will not receive any proceeds from the sale.

According to a document filed with the US Securities and Exchange Commission, the selling shareholders include Andris Zoltners, co-chairman of consulting firm ZS Associates and a member of the firm's board of directors, and funds controlled by Viking Global Investors, Matrix Capital Management, and Senator Investment Group. The shareholders have granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares at the offering price, less discounts and commissions.

In morning trading on the Nasdaq, shares of Adaptive were up 10 percent at $29.63.

JP Morgan, Goldman Sachs, and BofA Securities will act as joint lead book-running managers for the offering; Cowen, Guggenheim Securities, and William Blair will act as book-running managers; BTIG will act as comanager.

The offering is expected to close on Jan. 28, subject to customary closing conditions.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.